IGFBP3 promoter methylation in colorectal cancer: Relationship with microsatellite instability, CpG island methylator phenotype, and p53

Neoplasia

Volumn 9, Issue 12, 2007, Pages 1091-1098

  Kawasaki, Takako ^a   Nosho, Katsuhiko ^a   Ohnishi, Mutsuko ^a   Suemoto, Yuko ^a   Kirkner, Gregory J ^b   Fuchs, Charles S ^a,b   Ogino, Shuji ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CIMP; Colon cancer; IGFBP3; Methylation; MSI

Indexed keywords

CALCIUM CHANNEL T TYPE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; NEUROGENIN 1; PROTEIN BAX; PROTEIN MLH1; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 37149036252     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07760     Document Type: Article

References (49)

1. Giovannucci E (2003). Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 35, 694-704.
2. Perks CM, McCaig C, Clarke JB, Clemmons DR, and Holly JM (2002). A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem Biophys Res Commun 294, 988-994.
3. Hong J, Zhang G, Dong F, and Rechler MM (2002). Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277, 10489-10497.
4. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, et al. (2002). Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176, 149-158.
5. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, Naitou M, Doihara H, Kisimoto T, Katayama H, et al. (2007). Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 120, 566-573.
6. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, and Lee HY (2002). Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8, 3669-3675.
7. Wiley A, Katsaros D, Fracchioli S, and Yu H (2006). Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 16, 210-218.
8. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, and Kley N (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377, 646-649.
9. Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E, Ono T, and Koide N (2005). Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer 5, 9.
10. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, and Paraskeva C (2000). Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 60, 22-27.
11. Kansra S, Ewton DZ, Wang J, and Friedman E (2000). IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells. Int J Cancer 87, 373-378.
12. Peters I, Tossidou I, Achenbach J, Woroniecki R, Mengel M, Park JK, Paschy M, de Groot K, Haller H, and Schiffer M (2006). IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol 17, 1644-1656.
13. Rosendahl AH and Forsberg G (2006). IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells. Kidney Int 70, 1584-1590.
14. Laird PW (2005). Cancer epigenetics. Hum Mol Genet 14 (Spec No 1), R65-R76.
15. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, and Issa JP (1999). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96, 8681-8686.
16. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, and Ward R (2002). CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122, 1376-1387.
17. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, and Iacopetta B (2002). Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51, 797-802.
18. Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, Pandeya N, Young J, Meltzer SJ, Leggett BA, and Jass JR (2002). Morphological and molecular heterogeneity within nonmicrosatellite instability - high colorectal cancer. Cancer Res 62, 6011-6014.
19. Samowitz W, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, and Slattery ML (2005). Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129, 837-845.
20. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner G, Weisenberger DJ, Campan M, Laird PW, Loda M, and Fuchs CS (2006). CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55, 1000-1006.
21. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, and Ogino S (2007). Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 9, 569-577.
22. Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, and Fuchs CS (2006). Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 30, 1175-1183.
23. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, and Fuchs CS (2007). Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9, 305-314.
24. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. (2006). CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38, 787-793.
25. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, and Fuchs CS (2007). TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol 38, 614-620.
26. Jass JR (2007). Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50, 113-130.
27. Ogino S and Goel A (2008). Molecular classification and correlates in colorectal cancer. J Mol Diagn, in press.
28. Colditz GA and Hankinson SE (2005). The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5, 388-396.
29. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, and Willett WC (2006). Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98, 451-459.
30. Chan AT, Ogino S, and Fuchs CS (2007). Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. New Engl J Med 356, 2131-2142.
31. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, and Fuchs CS (2005). Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7, 413-421.
32. Dietmaier W, Hartmann A, Wallinger S, Heinmoller E, Kerner T, Endl E, Jauch KW, Hofstadter F, and Ruschoff J (1999). Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 154, 83-95.
33. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, and Fuchs CS (2006). Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19, 59-68.
34. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58, 5248-5257.
35. Ogino S, Kawasaki T, Kirkner GJ, Loda M, and Fuchs CS (2006). CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 8, 582-588.
36. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, et al. (2006). Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8, 209-217.
37. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, and Laird PW (2000). MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28, E32.
38. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, and Fuchs CS (2007). CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 450, 529-537.
39. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, and Fuchs CS (2006). Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 8, 458-464.
40. Camp RL, Charette LA, and Rimm DL (2000). Validation of tissue microarray technology in breast carcinoma. Lab Invest 80, 1943-1949.
41. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, and Fuchs CS (2007). Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 20, 15-22.
42. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, et al. (2005). Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 11, 6650-6656.
43. Hall PA and McCluggage WG (2006). Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 208, 1-6.
44. Litkouhi B, Kwong J, Lo CM, Smedley JG III, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, et al. (2007). Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9, 304-314.
45. Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, et al. (2007). Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia 9, 236-245.
46. Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, and Mok SC (2006). Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8, 268-278.
47. Liu Y, Lan Q, Siegfried JM, Luketich JD, and Keohavong P (2006). Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8, 46-51.
48. Chen J, Rocken C, Lofton-Day C, Schulz HU, Muller O, Kutzner N, Malfertheiner P, and Ebert MP (2005). Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis 26, 37-43.
49. Ebert MP, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J, Rocken C, Schulz HU, Malfertheiner P, and Lofton-Day C (2005). Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia 7, 771-778.